Three independent discounted-cash-flow-style models value CorMedix Inc. every trading day. 0 of 3 currently price CRMD above its market price.
| Free Cash Flow model | $-65,131.94 |
| Excess Profit model | $-87,125.83 |
| Residual Earnings model | $0.16 |
| Dividend Discount model | — |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +18.2% |
| Net debt / EBITDA | 1.6× |
| Gross margin | +92.9% |
| Revenue CAGR | +1077.5% |
| Cash conversion | 1.1× |
| Dividend yield | — |
| Buyback yield | +99.9% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open CRMD in StockKitty